APD 588
Alternative Names: APD-588Latest Information Update: 28 Jun 2023
At a glance
- Originator Arena Pharmaceuticals
- Developer Pfizer
- Class Anti-inflammatories; Antiasthmatics; Heart failure therapies; Small molecules
- Mechanism of Action Immunosuppressants; Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Heart failure
- No development reported Asthma